The app comprises part of the mylife Loop automated insulin delivery system. The iOS launch allows people with type 1 diabetes to easily and discreetly manage their pump on iPhones.
Ypsomed and CamDiab plan to begin a rollout of mylife Loop on iOS on March 24. It begins in Sweden through a pilot launch. Subsequently, it plans to expand to other countries.
During the pilot phase, the companies will offer mylife Loop with Abbott’s FreeStyle Libre 3 and Libre 3 Plus. They plan for an integration with the Dexcom G6 sensor to follow. After the pilot launch, they plan to bring the app on iOS to the rest of Europe. Then, they plan for Australia and Canada to follow throughout 2025.
The FDA approved CamDiab’s mylife CamAPS FX app last May but the companies offered no details on an iOS rollout in the U.S.
mylife Loop’s algorithm runs on a personal smartphone and is approved for type 1 diabetes from one year of age, depending on the sensor used for continuous glucose monitoring (CGM). It’s also the only algorithm indicated for pregnant women with type 1 diabetes in Europe and New Zealand.
“The introduction of the iOS version of the mylife Loop solution is an important step towards the wider availability of AID solutions for the treatment management of type 1 diabetes,” said Sébastien Delarive, Ypsomed Diabetes Care chief business officer.
CamDiab Director Roman Hovorka said the expansion marks a major milestone in making automated insulin delivery more accessible.
“Our goal is to provide a seamless, user-friendly experience that empowers individuals to better manage their condition with greater flexibility and convenience,” Hovorka said.
